What is Arkea Bio?
Arkea Bio operates at the intersection of biotechnology and environmental sustainability, focusing on the development of a scalable, cost-effective vaccine designed to mitigate methane emissions in cattle. By successfully demonstrating a proof-of-concept, the company has distinguished itself as a leader in agricultural bioscience. Its solution is engineered for rapid deployment, offering a unique value proposition to farmers, global food brands, and climate-conscious consumers. The company's market position is defined by its ability to bridge the gap between high-impact climate mitigation and the practical, economic realities of the global livestock industry, effectively turning a major greenhouse gas source into a manageable component of sustainable food production.
How much funding has Arkea Bio raised?
Arkea Bio has raised a total of $52.5M across 4 funding rounds:
Angel/Seed
$12M
Series A
$26.5M
Series A
$7M
Stock/Share Issuance
$7M
Angel/Seed (2022): $12M with participation from Breakthrough Energy Ventures
Series A (2024): $26.5M led by Rabo Frontier Ventures, Breakthrough Energy Ventures, and Overview Capital
Series A (2025): $7M supported by AgriZeroNZ and Breakthrough Energy Ventures
Stock/Share Issuance (2025): $7M, investors not publicly disclosed
Key Investors in Arkea Bio
Breakthrough Energy Ventures
Backed by global business leaders, this firm invests in cutting-edge companies aimed at achieving net-zero emissions through transformative clean energy and agricultural innovations.
Rabo Frontier Ventures
A specialized investment fund of Rabobank focusing on high-growth Fintech and Agtech companies that disrupt or influence the future of the agricultural financial landscape.
AgriZeroNZ
A public-private partnership dedicated to equipping farmers with innovative tools to reduce agricultural emissions while maintaining global competitiveness and profitability.
What's next for Arkea Bio?
With this major enterprise-level funding, Arkea Bio is well-positioned to accelerate its path toward commercialization and global distribution. The strategic roadmap likely involves scaling manufacturing capabilities to meet the immense demand for its methane-reduction solution, alongside navigating regulatory pathways in key agricultural markets. By leveraging its robust backing from climate-focused venture firms and agricultural partners, the company is set to refine its vaccine delivery systems and expand its reach to cattle populations worldwide. The focus remains on maintaining its competitive edge as the only viable, scalable solution for agricultural methane abatement, ensuring that the firm remains a central player in the transition to net-zero emissions by 2050.
See full Arkea Bio company page
